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Abstract  40 
Background 41 
Oropharyngeal cancer incidence is rapidly rising due to human papillomavirus (HPV) 16 42 
infection. The dearth of data on effectiveness of national girl-only vaccination program in 43 
preventing oral HPV infection and the potential herd immunity effect on unvaccinated boys has 44 
resulted in considerable controversy regarding the need to vaccinate boys, especially in countries 45 
with high vaccination coverage of girls.  46 
Methods 47 
Subjects aged 0-65 years undergoing tonsillectomy for non-malignant indications were recruited 48 
in 6 UK hospitals. Oral samples were collected in following order: oral rinse, tongue base and 49 
pharyngeal wall brushes, then tonsil tissue (tonsillectomy). Vaccination data was obtained from 50 
regional health authorities. All samples were centrally tested for HPV-DNA by PCR 51 
amplification. (NCT01330147). 52 
Results 53 
Of 940 subjects, 243 girls and 69 boys were aged 12-24; median age 18.6 years. 189 (78%) girls 54 
and no boys received HPV vaccination. Overall, oropharyngeal-HPV16 prevalence in vaccinated 55 
girls was significantly lower than unvaccinated girls (0.5% vs 5.6%, p=0.04). In contrast, 56 
prevalence of any oropharyngeal-HPV type was similar in vaccinated and unvaccinated girls 57 
(19% vs 20%, p=0.76). Oropharyngeal-HPV16 prevalence in (unvaccinated) boys was similar to 58 
vaccinated girls (0% vs 0.5%, p>0.99), and lower than unvaccinated girls (0% vs 5.6%, p=0.08).  59 
Conclusions 60 
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Our findings indicate that the UK girl-only national vaccination program is associated with 61 
significant reductions in oropharyngeal-HPV16 infections in children and young adults. This is 62 
also the first data to suggest potential herd immunity from girl-only vaccination against 63 
oropharyngeal HPV infection in contemporaneously-aged boys.  64 
 65 
  66 
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Introduction  67 
Infection with human papillomaviruses (HPV) can cause oropharyngeal cancers, as well as 68 
cervical, anal, penile, and vulvovaginal cancers, and genital warts. HPV is the main cause for the 69 
increasing incidence of oropharyngeal cancers in the USA and many Western European 70 
countries[1-5], and affects three times as many men than women. HPV16 has been identified as 71 
the primary type causing these cancers[4, 5]. Three HPV vaccines are now licensed in many 72 
countries worldwide; the HPV-16/18 AS04-adjuvanted vaccine (AS04-HPV-16/18v, Cervarix, 73 
GSK) and the four- (4vHPVv) and nine-valent (9vHPVv) Sulfate d'hydroxyphosphate 74 
d'aluminium-adjuvanted vaccines (Gardasil, Merck). These vaccines have been shown to prevent 75 
anogenital HPV16/18 infection and high-grade cervical and anogenital lesions[6-11]. The AS04-76 
HPV-16/18 vaccine targets two types of HPV that together cause more than 70% of cervical 77 
cancer (HPV16 and 18) and has also shown cross-protection against HPV types 31, 33, and 45, 78 
the next most common HPV types in cervical cancer[12-15]. As well as HPV16 and 18, the 79 
4vHPV vaccine targets HPV6 and 11, which cause over 86% of genital warts[16]. The 9vHPV 80 
vaccine (against HPV-6/11/16/18/31/33/45/52/58) has also been recently approved in many 81 
countries[17]. 82 
 83 
HPV vaccination was first introduced in the UK in September 2008, with AS04-HPV-16/18v 84 
offered to all girls aged 12-13 years (UK Year 8) as well as all girls aged 14-17 as part of a time-85 
limited catch-up program, with a switch to 4vHPV vaccine in September 2012. HPV vaccination 86 
in UK girls has had high uptake with 77% of 12-13 year-olds and 49% of 14-17 year-olds in the 87 
“catch-up” cohort having received all three doses[18].  88 
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In addition to trial data demonstrating that HPV vaccination effectively reduces cervical HPV 89 
infection and precancerous lesions, there have now been several studies showing population 90 
effects of national vaccination program. A systematic review and meta-analysis and several 91 
studies of the impact of national immunization program have shown considerable reductions in 92 
the risk of cervical HPV16/18 and HPV31/33/45 infections, anogenital warts, and cervical 93 
abnormalities (including invasive HPV-associated cancers) among women vaccinated before 20 94 
years of age[15, 19-24].  95 
To date, the effect of vaccination on oral HPV infection has not been well explored. Secondary 96 
analysis of a randomized controlled trial assessing AS04-HPV-16/18 vaccine efficacy on cervical 97 
HPV in Costa Rica[25] demonstrated  that vaccination was associated with a 93% (95% CI 63% -98 
100%) decrease in the prevalence of oral HPV16/18 in adult women four years after vaccination. 99 
More recently, evidence has been reported supporting reduced HPV6/11/16/18 oral prevalence 100 
rates in vaccinated compared to unvaccinated 18-33 year old subjects in the USA (0.11% vs 1.61 101 
%, p=0.08)[26]. Importantly, all studies have been carried out using oral rinse, and there have 102 
been no studies examining HPV prevalence using oral rinse and tonsil tissue together, or the 103 
effect of the vaccine on HPV prevalence in tonsil tissue (the primary site of oropharyngeal 104 
cancer). In addition, there have been no studies evaluating the efficacy of vaccination programs 105 
on oral HPV prevalence in children, or studying protection of boys from oral HPV infection by 106 
the potential herd effect from a national girl-only vaccination program. 107 
To address that, this study aimed to assess the effect of HPV vaccination on HPV prevalence in 108 
tonsillar tissue and oral exfoliated cells among girls and young adult women in the UK 109 
undergoing voluntary tonsillectomy for non-malignant indications, and to compare levels of 110 
infection to those of unvaccinated, contemporaneous young males of the same age. 111 
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Methods 112 
Study Design 113 
This paper uses data collected in the Oromouth study (NCT01330147), a cohort of 940 patients 114 
(340 males, 600 females) aged 0-65 years old undergoing tonsillectomy for non-malignant 115 
indications. Subjects were enrolled across 6 hospitals in the U.K. from 2013-2015. To assess 116 
vaccine effectiveness, we concentrated the analysis on female subjects aged 12-24 at enrollment 117 
who could have been vaccinated under the national UK HPV vaccination program, and on 118 
contemporaneous males of the same age. The West Midlands – Solihull National Health Service 119 
Research Ethics Committee approved this study (approval no 11/WM/0283) and all patients or 120 
parent(s)/legal guardian(s) gave written informed consent.  121 
 122 
Data Collection 123 
Oral samples were collected in the following order: oral mucosal transudate (using Oracol S10 124 
devices- Malvern Medical Developments) followed by a 60 second, sterile-saline oral rinse and 125 
gargle, then an oropharyngeal brush of the base of tongue (using Orcellex brushes; Rovers, The 126 
Netherlands), then an oropharyngeal brush of the posterior pharyngeal wall, and finally, all left 127 
and right tonsil tissue by tonsillectomy. Further details on collection and processing of all 128 
samples are provided in supplementary methods and figure S1. Urine, blood and nail brush 129 
samples were also collected pre-operatively (results not reported here). Samples were collected 130 
using pre-defined protocols by research nurses and surgeons who were trained before embarking 131 
on the study.  132 
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A standardized survey was completed by participants (sample shown in Figure S2, 133 
Supplementary Material). The survey included detailed demographic information, vaccination 134 
and clinical history, and for subjects 16 years and older sexual, smoking, and drinking behaviors.  135 
To avoid feelings of embarrassment and under-reporting by patients, surveys forms had unique 136 
identifiers only, with no names, and were submitted in closed envelopes deposited in locked 137 
ballot-type boxes, only to be opened by researchers who were independent and did not know the 138 
clinical teams. 139 
Data on vaccination was obtained from the regional health authorities that provided information 140 
on which patients received vaccination through the school program and the catch-up program, 141 
and how many doses they received.  142 
A study log was maintained to record those approached to be part of the Oromouth study and to 143 
record reasons for lack of consent. A total of 1356 individuals were approached, of which 71.6% 144 
consented. The main reasons for not gaining consent were patients refusing (38.9%) and parents 145 
declining (21.5%). Of this cohort, 30 patients were part of a pilot study and were therefore not 146 
included in the analysis for the main study.  147 
 148 
Processing and HPV testing of samples 149 
All samples were tested centrally for the presence of HPV DNA by PCR amplification using the 150 
HPV SPF10 PCR-DEIA (DNA enzyme immunoassay)-LiPA25 (Line probe assay) version 1 151 
(Laboratory Biomedical Products, Rijswijk, The Netherlands). Briefly, this broad-spectrum PCR-152 
based HPV DNA testing system uses SPF10 primers to amplify and a DNA enzyme immunoassay 153 
to detect at least 57 HPV genotypes and the LiPA25 line probe assay to genotype 25 carcinogenic 154 
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and non-carcinogenic HPVs in all samples (HPV types 6, 11, 16, 18, 31, 33 to 35, 39, 40, 42 to 155 
45, 51 to 54, 56, 58, 59, 66, 68, 70, and 74)[27, 28]. To increase the specificity of type-specific 156 
detection of HPV using the SPF10 DEIA system, all specimens that were SPF10 PCR/DEIA-157 
positive were tested with the E6-based multiplex type-specific system (MPTS123) that uses 158 
xMAP technology (Luminex, Austin, TX, USA)[29]. The HPV types detected by the MPTS123 159 
assay are HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 6, and 11). See 160 
Supplementary materials for details. 161 
Oropharyngeal HPV positivity was defined as HPV DNA detection in any of the collected oral 162 
samples (oral rinse, either of the oral brushes, or the tonsillar tissue samples) regardless of type. 163 
Oncogenic, or high-risk HPV (HR-HPV) was defined as types 16, 18, 31, 33, 35, 39, 45, 51, 52, 164 
58, or 59 based upon previous work.[30]  165 
 166 
Risk of bias mitigation 167 
Consecutive patients were recruited to avoid bias. Samples were analyzed at laboratories in a 168 
blinded fashion, with no knowledge of patient characteristics or behaviors. Questionnaires were 169 
collected and analyzed in a pseudo-anonymized manner, as described above. 170 
 171 
Statistical Analysis 172 
In this pre-specified analysis of secondary outcome measures, demographic characteristics, risk 173 
factors, and sample-specific HPV prevalence for girls and boys aged 12-24 years were compared 174 
by vaccination status and tested for differences using Pearson’s chi-squared tests or Fisher’s 175 
10 
 
Exact test. The following HPV type-specific outcomes for prevalence were compared between 176 
differences by vaccinated and unvaccinated subjects and by sample type: HPV16, HPV16/18, 177 
HPV31/33/45, any oncogenic HPV, and any HPV. To explore previously found cross-protective 178 
effects of Cervarix (AS04-HPV-16/18v) vaccination[12-14] with HPV types 31, 33, and/or 45, 179 
positivity to these types was considered as a separate outcome.  Logistic regressions were 180 
performed for each of the outcomes to test the association between vaccination and prevalence of 181 
HPV after controlling for age. Because behavioral factors were collected for subjects aged 16 and 182 
above, there were insufficient vaccinated patient numbers to undertake multiple logistic 183 
regressions to adjust for behavioral factors.  184 
  185 
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Results 186 
Of the 940 subjects in the study, there were 243 girls and 69 boys aged 12-24, with a median age 187 
of 18.6 years (Interquartile range 16.3-20.7) and 19.1 years (IQR=15.0-21.0) respectively. Of the 188 
girls, 189 (78%) received HPV vaccination. None of the boys were vaccinated. Girls who were 189 
vaccinated were more likely than unvaccinated girls to be white (90% vs 76%, p=0.03) and <20 190 
years old at enrollment (70% vs. 54%, p=0.01), but were similar in terms of enrollment center, 191 
year enrolled, and sexual behavior. 89% of those vaccinated received the AS04-HPV-16/18 192 
vaccine (Table 1).   193 
Effect of vaccination on HPV prevalence 194 
HPV prevalence was compared in vaccinated and unvaccinated girls, by HPV type and by sample 195 
type (Figure 1, Table 2). Overall oropharyngeal HPV16 prevalence was significantly lower in 196 
vaccinated than unvaccinated girls (0.5% vs 5.6%, p=0.04). Prevalence of oropharyngeal HPV16 197 
appeared lower among vaccinated than unvaccinated girls in both the routine and catch-up 198 
vaccination cohorts (Table S1). Prevalence of oropharyngeal HPV16 and/or 18 together (1.1% vs 199 
5.6%, p=0.07) also appeared to be reduced (Figure 1). All four participants who had 200 
oropharyngeal HPV16 infections had HPV16 detected in tonsillar tissue. Only one of these 201 
participants with tonsillar HPV16 had HPV16 detected in an oral rinse sample. Of the four 202 
participants with oropharyngeal HPV 16 infections, three were unvaccinated and one was 203 
vaccinated participant. The vaccinated participant was a girl who was 20 years old when she 204 
enrolled in the study in 2015, reported receiving 3 doses of AS04-HPV-16/18v, had 8 oral sex 205 
partners, and was a current smoker. One (vaccinated) participant had an oropharyngeal HPV18 206 
infection detected in an oral brush sample.    207 
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Oropharyngeal prevalence of HPV31, 33, and/or 45 was 0% in vaccinated girls compared to 208 
1.9% (1 case) in unvaccinated girls (p=0.22). Prevalence of any type of oropharyngeal HPV 209 
(19% vs 20%, p=0.76) or any oncogenic HPV type (7.4% vs. 7.4%, p>0.99) was similar in 210 
vaccinated and unvaccinated girls. Adjustment for age did not change results materially (Table 211 
S2). 212 
Next, HPV prevalence among unvaccinated boys 12-24 years of age was compared to that among 213 
unvaccinated and vaccinated girls of the same ages. There were no oropharyngeal HPV16 or 214 
HPV18 infections detected among boys. Indeed, oropharyngeal HPV16 prevalence in boys 215 
appears to be similar to vaccinated girls (0% vs0.5%, p>0.99), and lower than unvaccinated girls 216 
(0% vs 5.6%, p=0.08) (Figure 1, Table 2). Among 84 older males in the study, aged 25 to 56, 217 
prevalence of oropharyngeal HPV16 (7.1%, p=0.03), and of combined oropharyngeal HPV16 218 
and/or HPV18 infections (8.3%, p=0.02), were significantly higher than that observed among the 219 
12-24 year old boys (Figure 2, Table S3). 220 
 221 
Effect of vaccination by sample type  222 
When considering each sample type separately, HPV16 prevalence in tonsillar tissue samples was 223 
significantly lower in vaccinated than unvaccinated women aged 12-24 years (HPV16: 0.5% vs 224 
5.6%, p=0.04). Only one non-HPV16 type was detected in tonsillar samples in this age group, an 225 
HPV6 infection in a participant aged 17 years who received 3 doses of AS04-HPV-16/18v. When 226 
considering HPV16 in oral rinse samples alone, smaller differences were seen between 227 
vaccinated girls aged 12-24 years old, compared to unvaccinated ones (0% vs 1.9%, p=0.44) 228 
(Table 2). HPV detection in oropharyngeal brushes was low, with no HPV16 being detected. 229 
230 
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Discussion  231 
Our findings are the first to indicate that routine vaccination against HPV, as part of a national 232 
program, is associated with reductions in oropharyngeal HPV16 infections (the primary HPV 233 
type linked to oropharyngeal cancers) in children and young adults. Specifically, vaccination 234 
reduces the prevalence of tonsillar HPV infections, which is the commonest site of oropharyngeal 235 
cancer and for which data has hitherto been lacking. This data are consistent with data in adults 236 
from post-hoc analyses of the GSK HPV-040 study[31]; with a randomized controlled trial in 237 
Costa Rica[25] and with recent data from the USA[32].  The differences in oropharyngeal 238 
HPV16 infection shown within this relatively small study population suggests that the population 239 
impact of the UK vaccination program on oropharyngeal HPV is likely to be substantial.  240 
Importantly, our data also demonstrate low HPV16 prevalence amongst unvaccinated boys aged 241 
12-24 years old. Boys’ prevalence rates were similar to rates in vaccinated girls, and considerably 242 
lower than in unvaccinated girls and males aged 25 and over, despite boys reporting significantly 243 
more sexual activity (ever had sex) and more sexual partners than vaccinated girls. This effect 244 
was also demonstrated despite a likely reduction in prevalence rates in unvaccinated girls due to 245 
the potential herd effect from vaccinated girls, as demonstrated for cervical infections in 246 
Scotland, England and the Netherlands[15, 21, 23, 24, 33]. Previously, the only evidence of any 247 
potential herd immunity in males from the UK girls vaccination program was a reported 62% 248 
reduction in genital warts in heterosexual boys and young men in England since 2009[34]. Our 249 
data may be one of the first indications of a potential herd immunity effect from the girls-only 250 
vaccination program on oropharyngeal HPV infection in contemporaneously-aged boys.  If 251 
confirmed in larger population based studies, these new findings could carry important 252 
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implications for the decision to extend national HPV vaccination programs to include boys, 253 
where there is high coverage of girls.  254 
 255 
No previous study has had the opportunity to prospectively test tonsillar tissue for HPV in 256 
vaccinated and unvaccinated individuals. The few studies available were undertaken 257 
retrospectively on formalin fixed tissue samples from historic cohorts and have reported rates of 258 
0-1%[35-37]. By including tonsillar samples in our combined oropharyngeal HPV outcome, we 259 
were able to detect HPV in participants with greater sensitivity than by oral rinse alone. We were 260 
therefore able to find HPV in considerably more subjects, enabling us to detect a compelling 261 
difference in HPV16 prevalence between the vaccinated and unvaccinated groups in the tissue 262 
expected to be most relevant for disease. These results suggest that current estimates of oral 263 
HPV16 prevalence rates, based predominantly on oral rinse samples, may be an under-estimate of 264 
the true prevalence. It should be noted that more HPV16 was identified in tonsils than oral rinse 265 
samples, whereas HPV subtypes overall were identified much more commonly in oral rinse than 266 
tonsil samples. This may reflect a predilection of HPV16 to tonsils, compared to other HPV 267 
subtypes. 268 
Our study had limitations in that there were a small number of people with infection, especially 269 
for non-HPV16 oncogenic types, which limited the analyses and adjustments that could be 270 
undertaken. There was only one HPV18 case (in a vaccinated girl) and only one HPV31/33/45 271 
infection detected in our study (in an unvaccinated girl), so we could not make reliable 272 
conclusions for non-HPV16 oncogenic infections or adequately evaluate the cross-protective 273 
effects that have been found in previous studies[12-14]. However, these are rare causes of HPV-274 
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related oropharyngeal cancer. Furthermore, only participants aged 16 and older at enrollment 275 
completed the risk behavior survey, and we therefore could not adjust for these factors in our 276 
overall analysis without severely truncating our dataset. This means that residual confounding 277 
could remain in the estimates from the logistic regression. However, when restricting analyses to 278 
those who completed the survey and adjusting for behavioral risk factors, the results were of a 279 
similar magnitude to those displayed by the whole sample (Table S2). Furthermore, we 280 
undertook multiple analysis of secondary outcomes, with no control for multiplicity of 281 
inferences, which should be kept in mind when interpreting these results. Despite these 282 
limitations above, our results demonstrated convincing differences. Finally, more girls aged 12-283 
24 were recruited compared to boys. This reflects a lower willingness of boys to agree to 284 
participate in the study. This may introduce biases, albeit the prevalence of overall HPV and 285 
importantly all (sexually transmitted) high risk HPV infections was the same in girls and boys of 286 
the same age (data not shown) suggesting that the differences seen in HPV16prevalence were not 287 
due to recruitment bias.  288 
 289 
While the UK vaccination program was designed to prevent cervical cancers in women, the 290 
secondary effects of preventing oropharyngeal HPV infection are important to consider. With a 291 
rising public health focus on preventing HPV-positive oropharyngeal cancers due to their 292 
increasing incidence,[38] the effective reduction in oropharyngeal HPV16 prevalence in 293 
vaccinated adolescents and young adults seen in our study means that national vaccination 294 
programs could considerably reduce the incidence of oropharyngeal HPV cancers.  Our study 295 
also demonstrated reduced oropharyngeal HPV16 prevalence in the vaccinated groups of both the 296 
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routine and catch-up vaccine programs. As with cervical cancer, however, longitudinal data are 297 
necessary to fully establish the effectiveness of vaccination for preventing oropharyngeal cancers.  298 
In summary, our results are one of the first to show that a girl-only vaccination program protects 299 
against oncogenic oropharyngeal HPV16 infection in girls and young women, and may also 300 
confer protection on contemporaneously-aged unvaccinated boys through potential herd 301 
immunity. This suggests that oropharyngeal HPV prevalence may be reduced by girl-only 302 
national HPV vaccination programs with high coverage. 303 
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Tables 447 
Table 1: Description of boys and girls ages 12-24 in study population, with data on girls by HPV 448 
vaccination history. 449 
 Girls Boys 
 Received HPV Vaccine P-value 
Unvaccinated 
vs vaccinated 
girls 
Number (%) 
(n=69) 
P-value 
Boys vs 
vaccinated 
girls Participant Characteristic 
No 
(n = 54) 
Yes 
(n = 189) 
Age, in years    0.01  0.02 
    12-15 16 (29.6%) 41 (21.7%)  21 (30.4%)  
    16-19 13 (24.1%) 92 (48.7%)  20 (29.0%)  
    20-24 25 (46.3%) 56 (29.6%)  28 (40.6%)  
Ethnicity   0.03  0.38 
White 41 (75.9%) 171 (90.5%)  59 (85.5%)  
Black or Black British Mixed 2 (3.7%) 4 (2.1%)  5 (7.3%)  
Asian or British Asian 5 (9.3%) 5 (2.7%)  2 (2.9%)  
Mixed or Other Ethnic Group 6 (11.1%) 9 (4.8%)  3 (4.4%)  
Centre Enrolled   0.35  0.78 
    Worcester Royal Hospital 1 (1.9%) 6 (3.2%)  2 (2.9%)  
    University Hospital Coventry and 
Warwickshire 
27 (50.0%) 66 (34.9%)  
 
31 (44.9%) 
 
    University Hospital Birmingham 13 (24.1%) 63 (33.3%)  20 (29.0%)  
    New Cross Hospital 
Wolverhampton 
2 (3.7%) 4 (2.1%)  1 (1.5%)  
    Kidderminister General Hospital 1 (1.8%) 10 (5.3%)  4 (5.8%)  
    Birmingham Heartlands Hospital 10 (18.5%) 40 (21.2%)  11 (15.9%)  
24 
 
Year enrolled   0.60  0.16 
    2013 17 (31.5%) 66 (34.9%)  23 (33.3%)  
    2014 23 (42.6%) 86 (45.5%)  25 (36.2%)  
    2015 14 (25.9%) 37 (19.6%)  21 (30.4%)  
SURVEY AMONG THOSE ≥16 YEARS ONLY 
Age at First Sex, in years mean (SD) 16.2 (1.7) 15.9 (1.5) 0.24 16.2 (1.3) 0.12 
Ever had Sex   0.31  0.57 
      No 1 (2.9%) 14 (10.3%)  3 (6.5%)  
      Yes 34 (97.1%) 122 (89.7%)  43 (93.5%)  
Ever had Oral Sex   0.08  0.09 
      No 2 (6.5%) 25 (19.7%)  3 (7.1%)  
      Yes 29 (93.5%) 102 (80.3%)  39 (92.9%)  
Number of oral sex partners in 
lifetime 
  0.09  0.02 
      0 3 (10.7%) 26 (21.1%)  7 (46.7%)  
      1 8 (28.6%) 24 (19.5%)  1 (6.7%)  
      2-5 16 (57.1%) 51 (41.5%)  2 (13.3%)  
      6 or more 1 (3.6%) 22 (17.9%)  5 (33.3%)  
 450 
  451 
 452 
 453 
 454 
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Table 2: Difference in HPV prevalence among 69 unvaccinated boys, 189 girls vaccinated with 455 
any HPV vaccine and 54 unvaccinated girls aged 12-24 years old at enrollment, by sample type 456 
and among select HPV types. 457 
 
Girls  
Un-
vaccinated 
vs 
vaccinated 
girls 
Boys 
Boys vs. 
vaccinated  
girls 
Boys vs.  
non- 
vaccinated 
girls 
HPV Type and Sample Type 
Not Vaccinated
(N = 54) 
Yes Vaccinateda 
(N = 189b) P-value (N=69) 
 
P-value P-value 
HPV 16 
  Oropharyngeal (overall) 3 (5.6%) 1 (0.5%) 0.04 0 (0%) >0.99 0.08 
      Oral Rinse  1 (1.9%) 0 (0.0%) 0.22 0 (0%) -- 0.44 
      Oral Brush (either sample) 0 (0.0%) 0 (0.0%) -- 0 (0%) -- --  
        Tonsil  3 (5.6%) 1 (0.5%) 0.04 0 (0%) >0.99 0.08 
HPV 16 or 18 
   Oropharyngeal (overall) 3 (5.6%) 2 (1.1%) 0.07 0 (0%) >0.99 0.08 
      Oral Rinse  1 (1.9%) 0 (0.0%) 0.22 0 (0%) -- 0.44 
      Oral Brush (either sample) 0 (0.0%) 1 (0.5%) >0.99 0 (0%) >0.99 -- 
        Tonsil  3 (5.6%) 1 (0.5%) 0.04 0 (0%) >0.99 0.08 
HPV 31 or 33 or 45 
   Oropharyngeal (overall) 
 
1 (1.9%) 
 
0 (0.0%) 
 
0.22 1 (1.5%) 0.27 >0.99 
      Oral Rinse  1 (1.9%) 0 (0.0%) 0.22 0 (0%) -- 0.44 
      Oral Brush (either sample) 0 (0.0%) 0 (0.0%) -- 1 (1.5%) 0.27 >0.99 
        Tonsil  0 (0.0%) 0 (0.0%) -- 0 (0%) -- -- 
Any Oncogenic Type       
26 
 
aHPV16 was detected in the tonsil sample of 1 person who was vaccinated with AS04-458 
HPV16/18v (with 3 doses), reported having 8 lifetime oral sex partners, current smoker, and was 459 
enrolled in 2015 when she was 20 years old. Only 1 HPV18 infection was detected in any oral 460 
sample, it was in a AS04-HPV16/18v vaccinated participant who received all 3 doses, reported 461 
never performing oral sex or any other sexual activity, never smoker, and was enrolled in 2013 at 462 
age of 17.  463 
bTwo vaccinated subjects did not have tonsil samples (tonsillar data for vaccinated subjects 464 
shown is among 187 subjects). Three vaccinated subjects and one unvaccinated subject did not 465 
have oral rinse samples (oral rinse data for vaccinated and unvaccinated subjects shown is 186 466 
and 53, respectively). 467 
 468 
  469 
   Oropharyngeal  (overall) 4 (7.4%) 14 (7.4%) >0.99 2 (2.9%) 0.25 0.40 
      Oral Rinse  2 (3.7%) 12 (6.4%) 0.74 1 (1.5%) 0.20 0.58 
      Oral Brush (either sample) 0 (0.0%) 2 (1.1%) >0.99 1 (1.5%) >0.99 >0.99 
       Tonsil  3 (5.6%) 1 (0.5%) 0.04 0 (0%) >0.99 0.08 
Any type of HPV 
   Oropharyngeal (overall) 11 (20.4%) 35 (18.5%) 0.76 12 (17.4%) 0.84 0.67 
      Oral Rinse  8 (14.8%) 28 (14.8%) >0.99 9 (13.2%) 0.72 0.77 
      Oral Brush (either sample) 1 (1.9%) 8 (4.2%) 0.69 3 (4.4%) >0.99 0.63 
       Tonsil  3 (5.6%) 2 (1.1%) 0.07 1 (1.5%) >0.99 0.32 
27 
 
Figures 470 
Figure 1: Oropharyngeal HPV prevalence in unvaccinated girls, vaccinated girls, and boys aged 471 
12-14 years by vaccination status and HPV type. P values represent comparisons to unvaccinated 472 
girls using Pearson’s chi-squared tests or Fisher’s Exact test. 473 
 474 
Figure 2: Oropharyngeal HPV prevalence in males 12-24 years of age and males over 24 years 475 
old and by HPV type. P values represent comparisons to males 12-24 years old using Pearson’s 476 
chi-squared tests or Fisher’s Exact test. 477 
